Amgen

Open: 287.88 Close: 285.88 Change: -2.01

You're losing the opportunity of using an AI to get informed about Amgen.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Inc, year, biotechnology, company, price, earnings, and the most common words in the summary are: amgen, stock, market, price, amgn, top, inc, . One of the sentences in the summary was: announced financial results for the fourth quarter and full year 2023 versus comparable periods …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. Goldman Sachs continues with their Buy rating on Amgen, maintaining a Buy rating. Wall Street analysts forecast Amgen stock price to rise over the next year.

Today's News

Amgen Inc. per Employee $1.049M P/E Ratio 22.93 EPS $12.48 Yield 3.14% Dividend $2.25 Ex-Dividend Date Feb 15, 2024 Short Interest 9.3M 01/31/24 % of Float Shorted 1.74% Average Volume 2.68M Performance 5 Day -1.85% 3 month 8th ( CBS goofYeahefullyurities Nebula merge stats efficiently standings showed Amgen Inc. announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. Amgen said its adjusted fourth-quarter profit rose 15%. Amgen Inc. is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. BioAge has closed a $170 million series D led by Sofinnova with contributions from major institutional biotech investors and the venture arms of both the Indianapolis pharma and Amgen. The financing is enough to last almost three years, at least, CEO Kristen Fortney, Ph.D., said in an interview with Fierce Biotech ahead of Tuesdays announcement. Amgen Inc. is down -0.38% at $290.01.01. With a volume of 694,355, the price of Amgen is down 0.97%. Goldman Sachs continues with their Buy rating on Amgen, maintaining a Buy rating. Julia Walker Vice President Corporate Affairs at Amgen is recruiting for a Science Writer. Amgens new podcast Undruggable explores the latest wave of innovation. Amgen Corporate Affairs is recruiting... principal web cloud solutions architect – us remote jobs at amgen in united states - remote. Meeting and Contracting Capability Manager responsible for efficiently managing daily meetings and providing contracting support across various functions at Amgen. Amgen is one of the worlds leading independent biotechnology companies. For over 4 decades, Amgen has pioneered biotechnology breakthroughs, to bring state-of-the-art medicines from laboratory to the patient. Scam Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Amgen is expected to release next earnings on 05/02/2024 with an earnings per share estimate of $4.00. Amgen (AMGN) pay a dividend of $ 2.25 per share of Class A Common Stock. Q1 earnings are confirmed for April 25, 2024. The intrinsic value of one AMGN stock under the Base Case scenario is 242.85 USD. Compared to the current market price of 286.23 USD , Amgen Incis Overvalued by 15%. Wall Street analysts forecast AMgen stock price to rise over the next year. Amgen is an Equal Opportunity Employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability. Leerink downgraded Amgen due to high expectations from its weight loss drug R&D program. Leerinks downgraded the company due to expectations from high expectations. Investors would be looking at Amgens plans to take on current leaders in the weight loss space.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, Inc, year, biotechnology, company, price, earnings, and the most common words in the summary are: amgen, stock, market, price, amgn, top, inc, . One of the sentences in the summary was: announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #price #amgn #top #inc.